Skip to main content
AAN.com
BRIEF COMMUNICATION
September 1, 1995

Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease
A double-blind, placebo-controlled study

September 1995 issue
45 (9) 1757-1760

Abstract

We investigated the effect of levodopa on mood and anxiety in eight Parkinson's disease patients with motor fluctuations.Each patient received 0.0-, 0.5-, and 1.0-mg/kg/hr levodopa infusions in randomly assigned order under double-blind conditions on consecutive days. Mood elevation and anxiety reduction based on half-hourly patient rating and a corresponding increase in tapping speed occurred with active drug infusion but not placebo infusion. The effects were dose related. The higher-dose infusion rate produced more rapid onset, greater magnitude, and longer duration of response. We conclude that mood and anxiety fluctuations related to levodopa dosing are robust pharmacologic, and not placebo, effects.
NEUROLOGY 1995;45: 1757-1760

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989;(suppl):29-37.
2.
Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-454.
3.
Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G. Depression in Parkinson's disease. Am J Psychiatry 1994;151:1010-1014.
4.
Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. ``Panic attacks'' in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand 1993;87:14-18.
5.
Henderson R, Kurlan R, Kersum JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:257-264.
6.
Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and ``On-off'' phenomena in Parkinson's disease. Mov Disord 1990;5:148-151.
7.
Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the ``on-off'' phenomenon in Parkinson's disease. Psychol Med 1987;17:899-904.
8.
Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion. Mov Disord 1995;10:329-332.
9.
Nutt JG, Woodward WR, Carter JH, Gancher ST. Effects of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-1130.
10.
McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988;18:1007-1019.

Information & Authors

Information

Published In

Neurology®
Volume 45Number 9September 1995
Pages: 1757-1760
PubMed: 7675241

Publication History

Published online: September 1, 1995
Published in print: September 1995

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

From the Departments of Psychiatry (Dr. Maricle and R. Valentine), Neurology (Dr. Nutt and J. Carter), and Pharmacology (Dr. Nutt), Oregon Health Sciences University, Portland, OR.
Supported in part by APDA Center for Advanced Research, R01-NS21062, and Clinical Research Center Grant RR00334.
Received November 18, 1994. Accepted in final form February 19, 1995.
Address correspondence and reprint requests to Dr. Robert A. Maricle, Department of Psychiatry--OP-02, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. ON/OFF non-motor evaluation: a new way to evaluate non-motor fluctuations in Parkinson’s disease, Journal of Neurology, Neurosurgery & Psychiatry, (jnnp-2023-332551), (2024).https://doi.org/10.1136/jnnp-2023-332551
    Crossref
  2. Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1242484
    Crossref
  3. Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies, npj Parkinson's Disease, 9, 1, (2023).https://doi.org/10.1038/s41531-023-00547-4
    Crossref
  4. Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study, Journal of Neural Transmission, 130, 11, (1463-1474), (2023).https://doi.org/10.1007/s00702-023-02609-6
    Crossref
  5. Behavioral disturbances in Parkinson's disease, Dialogues in Clinical Neuroscience, 6, 3, (323-332), (2022).https://doi.org/10.31887/DCNS.2004.6.3/kanderson
    Crossref
  6. Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson's disease and its medications, Future Journal of Pharmaceutical Sciences, 8, 1, (2022).https://doi.org/10.1186/s43094-022-00425-5
    Crossref
  7. Phenomenology of Atypical Anxiety Disorders in Parkinson's Disease: A Systematic Review, The American Journal of Geriatric Psychiatry, 30, 9, (1026-1050), (2022).https://doi.org/10.1016/j.jagp.2022.02.004
    Crossref
  8. Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson’s disease?, Neurological Sciences, 43, 6, (3641-3647), (2022).https://doi.org/10.1007/s10072-021-05833-8
    Crossref
  9. Probable REM Sleep Behavior Disorder Is a Risk Factor for Symptom Progression in Parkinson Disease, Frontiers in Neurology, 12, (2021).https://doi.org/10.3389/fneur.2021.651157
    Crossref
  10. Medical treatment of the motor features of Parkinson disease, Principles and Practice of Movement Disorders, (164-203.e14), (2021).https://doi.org/10.1016/B978-0-323-31071-0.00006-8
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share